经过渡期和绝经后激素治疗临床应用指南（Guidelines for clinical use of trans menopausal and postmenopausal hormone therapy）.docVIP

下载本文档

3
0
约1.22万字
约 12页
2017-09-02 发布于河南
举报
版权申诉

经过渡期和绝经后激素治疗临床应用指南（Guidelines for clinical use of trans menopausal and postmenopausal hormone therapy）.doc

1、本文档共12页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

经过渡期和绝经后激素治疗临床应用指南（Guidelines for clinical use of trans menopausal and postmenopausal hormone therapy）

经过渡期和绝经后激素治疗临床应用指南（Guidelines for clinical use of trans menopausal and postmenopausal hormone therapy） Guidelines for the clinical practice of hormone therapy after transition and menopause (revised version 2006), menopause branch of the obstetrics and Gynecology branch of the Chinese Medical Association First, the consensus on the application of HT in menopause 1., the use of HT is a necessary medical measure for menopausal related health problems. 2., menopause and related symptoms (such as vasomotor symptoms, urogenital atrophy symptoms, neuropsychiatric symptoms, etc.) are the primary indications for the use of HT, 3., HT is an effective method to prevent postmenopausal osteoporosis. 4., HT is not recommended for primary prevention of cardiovascular disease and does not apply to the two stage of coronary heart disease prevention. 5. for women with complete uterus, the right amount of progesterone should be used to protect the endometrium while estrogen is applied. Women who have already removed the uterus need not use progesterone. 6. when HT is applied, the minimum effective dose should be taken under the premise of considering the purpose and the risk of the treatment. 7. begin the application of HT in the presence of symptoms associated with menopause. Choose options according to individual circumstances. 8. there is no need to limit the duration of HT. An individual risk / benefit assessment should be carried out at least once a year with HT, depending on the assessment, the length of the course of treatment and the long-term application. 9.. When menopause related symptoms and other diseases occur, HT can be used to control complications at the same time. 10. there is not enough evidence to suggest that phytoestrogens can be used as an alternative to ET. 11., sex hormone therapy needs to follow the evidence-based medicine method, and constantly improve and revise the application program. Two. The specific content of clinical application guideline of HT 1. c